Evidence map›Paper›PMID 41994560›Full record

ArticleMolecular therapy. Oncology2026

A CRISPR-Cas13d cancer therapeutic enables selective elimination of uveal melanoma.

Daniel Stauber, Lucas Sosnick, Yitong Ma, Sopida Pimcharoen, Atip Lawanprasert, Niren Murthy, David Myung, Lei S Qi

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecular therapy. Oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

8 authors.

Daniel StauberDepartment of Bioengineering, Stanford University, Stanford, CA, USA.
Lucas SosnickDepartment of Bioengineering, Stanford University, Stanford, CA, USA.
Yitong MaDepartment of Bioengineering, Stanford University, Stanford, CA, USA.
Sopida PimcharoenDepartment of Bioengineering, Stanford University, Stanford, CA, USA.
Atip LawanprasertInnovative Genomics Institute, University of California, Berkeley, Berkeley, CA, USA.
Niren MurthyInnovative Genomics Institute, University of California, Berkeley, Berkeley, CA, USA.
David MyungDepartment of Ophthalmology, Byers Eye Institute at Stanford University, School of Medicine, Palo Alto, CA, USA.
Lei S QiDepartment of Bioengineering, Stanford University, Stanford, CA, USA.

Funding

Stanford Vision Research CoreP30EY026877 · NEI · STANFORD UNIVERSITY · PI Jeffrey L Goldberg · 2017 to 2026
$8.0M
Manipulating and Interrogating Spatial TranscriptomicsDP1NS137219 · NINDS · STANFORD UNIVERSITY · PI Lei Stanley Qi · 2023 to 2026
$4.3M
High resolution dissection of oncogene enhancer networks via CRISPR screening and live-cell imaging.R01CA266470 · NCI · STANFORD UNIVERSITY · PI Lei Stanley Qi · 2022 to 2026
$1.9M
NCI NIH HHS R01 CA266470NEI NIH HHS P30 EY026877NINDS NIH HHS DP1 NS137219
6 · The paper itself

Abstract

Uveal melanoma, the most common eye cancer in adults, remains limited to surgical intervention and radiotherapy, with a dismal survival rate that has not improved in over 50 years. To address this therapeutic impasse, we systematically analyzed public gene expression and CRISPR knockout datasets, identifying

Indexed as

cancer therapeuticCas13context-specific essential geneCRISPRgene therapyprecision tumor targetingRNA-targetingtherapeutic platformundruggableuveal melanoma

Identifiers

PMID41994560
PMCPMC13080610

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.